You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGlycerol
Accession NumberDB04077  (EXPT01027)
TypeSmall Molecule
GroupsExperimental
DescriptionA trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent. [PubChem]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIPDC6A3C0OX
CAS numberNot Available
WeightAverage: 92.0938
Monoisotopic: 92.047344122
Chemical FormulaC3H8O3
InChI KeyPEDCQBHIVMGVHV-UHFFFAOYSA-N
InChI
InChI=1S/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2
IUPAC Name
propane-1,2,3-triol
SMILES
OCC(O)CO
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Hematopoietic prostaglandin D synthaseProteinunknownNot AvailableHumanO60760 details
Endoglucanase GProteinunknownNot AvailableClostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)P37700 details
Glutathione S-transferase PProteinunknownNot AvailableHumanP09211 details
Group IIE secretory phospholipase A2ProteinunknownNot AvailableHumanQ9NZK7 details
Inositol-3-phosphate synthase 1ProteinunknownNot AvailableHumanQ9NPH2 details
C4-dicarboxylate transport transcriptional regulatory protein DctDProteinunknownNot AvailableEnsifer melilotiP13632 details
Alcohol dehydrogenase 1BProteinunknownNot AvailableHumanP00325 details
Inositol 1,4,5-trisphosphate receptor type 1ProteinunknownNot AvailableHumanQ14643 details
GlycodelinProteinunknownNot AvailableHumanP09466 details
Alpha-N-acetylgalactosaminidaseProteinunknownNot AvailableHumanP17050 details
Cytochrome c4ProteinunknownNot AvailablePseudomonas stutzeriQ52369 details
BacterioferritinProteinunknownNot AvailableDesulfovibrio desulfuricans (strain ATCC 27774 / DSM 6949)Q93PP9 details
TGF-beta receptor type-2ProteinunknownNot AvailableHumanP37173 details
Argininosuccinate synthaseProteinunknownNot AvailableEscherichia coli (strain K12)P0A6E4 details
EnolaseProteinunknownNot AvailableEnterococcus hiraeQ8GR70 details
ADP-ribosylation factor 1ProteinunknownNot AvailableHumanP84077 details
Multidrug resistance protein MexAProteinunknownNot AvailablePseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)P52477 details
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1ProteinunknownNot AvailableHumanO43252 details
Histidinol dehydrogenaseProteinunknownNot AvailableEscherichia coli (strain K12)P06988 details
DNA mismatch repair protein MutLProteinunknownNot AvailableEscherichia coli (strain K12)P23367 details
Glycerol uptake facilitator proteinProteinunknownNot AvailableEscherichia coli (strain K12)P0AER0 details
Ribonucleoside-diphosphate reductase 1 subunit betaProteinunknownNot AvailableEscherichia coli (strain K12)P69924 details
Adenine DNA glycosylaseProteinunknownNot AvailableEscherichia coli (strain K12)P17802 details
tRNA (cytosine(38)-C(5))-methyltransferaseProteinunknownNot AvailableHumanO14717 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Familial lipoprotein lipase deficiencyDiseaseSMP00530
GalactosemiaDiseaseSMP00182
Glycerolipid MetabolismMetabolicSMP00039
Galactose MetabolismMetabolicSMP00043
Glycerol Kinase DeficiencyDiseaseSMP00187
D-glyceric aciduraDiseaseSMP00529
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Glycerol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Glycerol.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Glycerol.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Glycerol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Glycerol.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Glycerol.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Glycerol.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Glycerol.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Glycerol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Glycerol.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Glycerol.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Glycerol.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Glycerol.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Glycerol.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Glycerol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Glycerol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glycerol.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Glycerol.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Glycerol.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Glycerol.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Glycerol.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Glycerol.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Glycerol.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Glycerol.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Glycerol.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Glycerol.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Glycerol.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Glycerol.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Glycerol.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Glycerol.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Glycerol.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Glycerol.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Glycerol.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Glycerol.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Glycerol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Glycerol.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Glycerol.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Glycerol.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Glycerol.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Glycerol.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Glycerol.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Glycerol.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glycerol.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Glycerol.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Glycerol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Glycerol.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Glycerol.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Glycerol.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Glycerol.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Glycerol.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Glycerol.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Glycerol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Glycerol.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Glycerol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Glycerol.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Glycerol.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Glycerol.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Glycerol.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Glycerol.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Glycerol.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Glycerol.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Glycerol.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Glycerol.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Glycerol.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Glycerol.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Glycerol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Glycerol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Glycerol.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Glycerol.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Glycerol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Glycerol.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Glycerol.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Glycerol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Glycerol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Glycerol.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Glycerol.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Glycerol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Glycerol.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Glycerol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Glycerol.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Glycerol.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Glycerol.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Glycerol.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Glycerol.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Glycerol.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Glycerol.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Glycerol.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Glycerol.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Glycerol.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Glycerol.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Glycerol.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Glycerol.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Glycerol.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Glycerol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Glycerol.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Glycerol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Glycerol.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Glycerol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Glycerol.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Glycerol.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Glycerol.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Glycerol.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Glycerol.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Glycerol.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Glycerol.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Glycerol.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Glycerol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Glycerol.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Glycerol.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Glycerol.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Glycerol.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Glycerol.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Glycerol.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glycerol.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Glycerol.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Glycerol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Glycerol.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Glycerol.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Glycerol.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Glycerol.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Glycerol.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Glycerol.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Glycerol.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Glycerol.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Glycerol.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Glycerol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Glycerol.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Glycerol.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Glycerol.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Glycerol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Glycerol.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Glycerol.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Glycerol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Glycerol.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Glycerol.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Glycerol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Glycerol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Glycerol.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Glycerol.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Glycerol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Glycerol.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Glycerol.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Glycerol.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Glycerol.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Glycerol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Glycerol.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Glycerol.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Glycerol.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Glycerol.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Glycerol.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Glycerol.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Glycerol.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Glycerol.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Glycerol.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Glycerol.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Glycerol.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Glycerol.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Glycerol.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Glycerol.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Glycerol.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Glycerol.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Glycerol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Glycerol.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Glycerol.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Glycerol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Glycerol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Glycerol.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Glycerol.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Glycerol.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Glycerol.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Glycerol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Glycerol.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Glycerol.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Glycerol.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Glycerol.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Glycerol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Glycerol.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Glycerol.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Glycerol.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Glycerol.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Glycerol.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Glycerol.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Glycerol.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Glycerol.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Glycerol.Approved
Food InteractionsNot Available
References
Synthesis Reference

Tatsuro Tsuneno, Masaaki Takaku, “Process for preparing boric esters of glycerol fatty acid esters.” U.S. Patent US4515725, issued March, 1968.

US4515725
General ReferencesNot Available
External Links
ATC CodesA06AG04A06AX01
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9239
Blood Brain Barrier-0.6136
Caco-2 permeable-0.8334
P-glycoprotein substrateNon-substrate0.7076
P-glycoprotein inhibitor INon-inhibitor0.9186
P-glycoprotein inhibitor IINon-inhibitor0.9572
Renal organic cation transporterNon-inhibitor0.9307
CYP450 2C9 substrateNon-substrate0.8881
CYP450 2D6 substrateNon-substrate0.8821
CYP450 3A4 substrateNon-substrate0.7971
CYP450 1A2 substrateNon-inhibitor0.7599
CYP450 2C9 inhibitorNon-inhibitor0.9482
CYP450 2D6 inhibitorNon-inhibitor0.9554
CYP450 2C19 inhibitorNon-inhibitor0.8847
CYP450 3A4 inhibitorNon-inhibitor0.9605
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9576
Ames testNon AMES toxic0.8278
CarcinogenicityNon-carcinogens0.6884
BiodegradationReady biodegradable0.8497
Rat acute toxicity0.8954 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.967
hERG inhibition (predictor II)Non-inhibitor0.928
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility1170.0 mg/mLALOGPS
logP-1.9ALOGPS
logP-1.8ChemAxon
logS1.1ALOGPS
pKa (Strongest Acidic)13.61ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity20.52 m3·mol-1ChemAxon
Polarizability8.93 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)splash10-0fr2-0910000000-6497c0870b71585c6322View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)splash10-0ktb-0920000000-93408d69acffad6f48afView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)splash10-05mk-0940000000-778ba583836705f8fdf4View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-00kb-0920000000-2e4b358941c660851f0aView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)splash10-00dj-6920000000-6828d7b00cb31e84fac1View in MoNA
GC-MSGC-MS Spectrum - GC-MS (3 TMS)splash10-0le9-0940000000-e0b9bada9be26d720326View in MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0a4i-9000000000-d7c139dc01453f61eb99View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0a4l-9000000000-7d7844b4813b038012daView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0udi-9100000000-16029dbe79f139ab904aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-01ox-9000000000-3fe0c184a891364773a8View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0006-9000000000-a638e26fe3c3f48563c2View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-004l-9000000000-d3fd9e9abd911eb0f88eView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0a6r-9000000000-ca218dca3a5d86196d81View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0006-9000000000-b40367f5ca8d11288fbeView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0006-9000000000-ba29a0647084e32d8704View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0abc-9000000000-4cd85379d414c16f95c0View in MoNA
MSMass Spectrum (Electron Ionization)splash10-01ox-9000000000-3706109441e6d3017895View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,1H] 2D NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassSugar alcohols
Direct ParentSugar alcohols
Alternative Parents
Substituents
  • Sugar alcohol
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Hydrocarbon derivative
  • Primary alcohol
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a wide range of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide.
Gene Name:
HPGDS
Uniprot ID:
O60760
Molecular Weight:
23343.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Clostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)
Pharmacological action
unknown
General Function:
Cellulose binding
Specific Function:
The biological conversion of cellulose to glucose generally requires three types of hydrolytic enzymes: (1) Endoglucanases which cut internal beta-1,4-glucosidic bonds; (2) Exocellobiohydrolases that cut the dissaccharide cellobiose from the non-reducing end of the cellulose polymer chain; (3) Beta-1,4-glucosidases which hydrolyze the cellobiose and other short cello-oligosaccharides to glucose.
Gene Name:
celCCG
Uniprot ID:
P37700
Molecular Weight:
79775.34 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
S-nitrosoglutathione binding
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name:
GSTP1
Uniprot ID:
P09211
Molecular Weight:
23355.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name:
PLA2G2E
Uniprot ID:
Q9NZK7
Molecular Weight:
15988.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Inositol-3-phosphate synthase activity
Specific Function:
Key enzyme in myo-inositol biosynthesis pathway that catalyzes the conversion of glucose 6-phosphate to 1-myo-inositol 1-phosphate in a NAD-dependent manner. Rate-limiting enzyme in the synthesis of all inositol-containing compounds.
Gene Name:
ISYNA1
Uniprot ID:
Q9NPH2
Molecular Weight:
61067.285 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Ensifer meliloti
Pharmacological action
unknown
General Function:
Sequence-specific dna binding
Specific Function:
Member of the two-component regulatory system DctB/DctD involved in the transport of C4-dicarboxylates. When activated by DctB acts in conjunction with sigma-54 to activate the transcription of dctA.
Gene Name:
dctD
Uniprot ID:
P13632
Molecular Weight:
50060.805 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
ADH1B
Uniprot ID:
P00325
Molecular Weight:
39854.21 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phosphatidylinositol binding
Specific Function:
Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. Involved in the regulation of epithelial secretion of electrolytes and fluid through the interaction with AHCYL1 (By similarity). Plays a role in ER stress-induced apoptosis. Cytoplasmic calcium released from the ER triggers apoptosis by the activation of CaM...
Gene Name:
ITPR1
Uniprot ID:
Q14643
Molecular Weight:
313926.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Small molecule binding
Specific Function:
This protein is, quantitatively, the main protein synthesized and secreted in the endometrium from mid-luteal phase of the menstrual cycle and during the first semester of pregnancy.
Gene Name:
PAEP
Uniprot ID:
P09466
Molecular Weight:
20624.015 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. Required for the breakdown of glycolipids.
Gene Name:
NAGA
Uniprot ID:
P17050
Molecular Weight:
46564.15 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Pseudomonas stutzeri
Pharmacological action
unknown
General Function:
Iron ion binding
Specific Function:
Diheme, high potential cytochrome c believed to be an intermediate electron donor to terminal oxidation systems.
Gene Name:
cc4
Uniprot ID:
Q52369
Molecular Weight:
21741.505 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Desulfovibrio desulfuricans (strain ATCC 27774 / DSM 6949)
Pharmacological action
unknown
General Function:
Ferroxidase activity
Specific Function:
Iron-storage protein, whose ferroxidase center binds Fe(2+) ions, oxidizes them by dioxygen to Fe(3+), and participates in the subsequent Fe(3+) oxide mineral core formation within the central cavity of the protein complex.
Gene Name:
bfr
Uniprot ID:
Q93PP9
Molecular Weight:
19881.14 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Type iii transforming growth factor beta receptor binding
Specific Function:
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial ...
Gene Name:
TGFBR2
Uniprot ID:
P37173
Molecular Weight:
64567.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Atp binding
Specific Function:
Not Available
Gene Name:
argG
Uniprot ID:
P0A6E4
Molecular Weight:
49898.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Enterococcus hirae
Pharmacological action
unknown
General Function:
Phosphopyruvate hydratase activity
Specific Function:
Catalyzes the reversible conversion of 2-phosphoglycerate into phosphoenolpyruvate. It is essential for the degradation of carbohydrates via glycolysis.
Gene Name:
eno
Uniprot ID:
Q8GR70
Molecular Weight:
46410.935 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein activity
Specific Function:
GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking among different compartments. Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein traff...
Gene Name:
ARF1
Uniprot ID:
P84077
Molecular Weight:
20696.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
Pharmacological action
unknown
General Function:
Drug transmembrane transporter activity
Specific Function:
The periplasmic linker component of the MexAB-OprM efflux system that confers multidrug resistance. Also functions as the major efflux pump for n-hexane and p-xylene efflux. Over-expression of the pump increases antibiotic and solvent efflux capacities. Required for assembly of the MexA/MexB/OprM complex. Implicated in the secretion of the siderophore pyoverdine.The ability to export antibiotic...
Gene Name:
mexA
Uniprot ID:
P52477
Molecular Weight:
40969.34 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sulfate adenylyltransferase (atp) activity
Specific Function:
Bifunctional enzyme with both ATP sulfurylase and APS kinase activity, which mediates two steps in the sulfate activation pathway. The first step is the transfer of a sulfate group to ATP to yield adenosine 5'-phosphosulfate (APS), and the second step is the transfer of a phosphate group from ATP to APS yielding 3'-phosphoadenylylsulfate (PAPS: activated sulfate donor used by sulfotransferase)....
Gene Name:
PAPSS1
Uniprot ID:
O43252
Molecular Weight:
70832.725 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Catalyzes the sequential NAD-dependent oxidations of L-histidinol to L-histidinaldehyde and then to L-histidine.
Gene Name:
hisD
Uniprot ID:
P06988
Molecular Weight:
46109.815 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Mismatched dna binding
Specific Function:
This protein is involved in the repair of mismatches in DNA. It is required for dam-dependent methyl-directed DNA mismatch repair. May act as a "molecular matchmaker", a protein that promotes the formation of a stable complex between two or more DNA-binding proteins in an ATP-dependent manner without itself being part of the final effector complex. The ATPase activity of MutL is stimulated by DNA.
Gene Name:
mutL
Uniprot ID:
P23367
Molecular Weight:
67923.04 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Water channel activity
Specific Function:
Transporter of glycerol across the cytoplasmic membrane, with limited permeability to water and small uncharged compounds such as polyols.
Gene Name:
glpF
Uniprot ID:
P0AER0
Molecular Weight:
29779.71 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor
Specific Function:
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. R2 contains the tyrosyl radical required for catalysis.
Gene Name:
nrdB
Uniprot ID:
P69924
Molecular Weight:
43516.885 Da
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Adenine glycosylase active on G-A mispairs. MutY also corrects error-prone DNA synthesis past GO lesions which are due to the oxidatively damaged form of guanine: 7,8-dihydro-8-oxoguanine (8-oxo-dGTP).
Gene Name:
mutY
Uniprot ID:
P17802
Molecular Weight:
39148.835 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Trna methyltransferase activity
Specific Function:
Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp).
Gene Name:
TRDMT1
Uniprot ID:
O14717
Molecular Weight:
44596.17 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, Sakuda SH, Nagasawa H, Shimizu M: Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol. 2004 Oct;143(3):379-87. Epub 2004 Sep 6. [PubMed:15351776 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:24